普利製藥(300630.SZ)與Celsion公司簽訂合作協議
格隆匯9月21日丨普利製藥(300630.SZ)公佈,公司於近日與美國生物製藥 Celsion Corporation(以下簡稱"Celsion 公司")簽署了關於 DNA疫苗的相關合作協議,雙方本着"平等自願、資源共享、優勢互補、協同發展"的原則開展合作,普利製藥將為 Celsion 公司生產 DNA 疫苗的臨牀批樣品以及在該產品獲得批准使用的商業批供貨。
公司與 Celsion 已合作多年,並建立了成功的合作關係,此次合作是繼第一次 DNA 新藥項目合作之後,公司與 Celsion 公司的二次合作,表明公司的核酸藥物製造能力獲得了 Celsion 公司的充分認可。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.